Halsa Pharma

Halsa Pharmaceuticals is a biotechnology company focused on developing next-generation therapies for obesity and metabolic disorders. Founded by a team of world-renowned scientists, including Robert Langer, Jens Juul Holst, and Stephen O'Rahilly, the company leverages a proprietary platform to identify novel pathways for weight regulation that are distinct from the GLP-1 mechanism. In September 2023, Amgen acquired Halsa Pharmaceuticals for $160 million in an upfront payment to bolster its cardiometabolic pipeline. The acquisition provides Amgen with a lead program that offers a potentially differentiated mechanism of action for treating obesity. Halsa's research aims to address the global health challenge of metabolic disease through innovative, first-in-class therapeutic assets.